Comparison of Bolus Versus Continuous Infusion of Terlipressin Cirrhotic Patients With Septic Shock.
Trial · NCT04819568
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Reversal of shock | 72 hours | DISCONTINUATION OF NOREPINEPHRINE IS CONSIDERED AS REVERSAL OF SHOCK. |
| Secondary | Time to reversal of shock | 1 Year | |
| Secondary | Incidence of adverse effects and discontinuation of therapy due to adverse effects | 24 hours | |
| Secondary | Incidence of adverse effects and discontinuation of therapy due to adverse effects | Day 3 | |
| Secondary | Impact on AKI (Progression, Resolution, requirement of renal replacement therapy, (RRT) | 24 hours | AS PER KDIGO STAZE, AKI HAS BEEN DEFINED. INCREMENT OF ONE OR MORE STAZE OR REQUIREMENT OF RRT IS CONSIDERED AS PROGRESSION. REMAINING SAME STAZE IS CONSIDERED AS PERSISTENT. DECREMENT OF ONE OR MORE STAZE IS CONSIDERED AS IMPROVEMENT. |
| Secondary | Impact on AKI (Progression, Resolution, requirement of renal replacement therapy, (RRT) | Day 3 | AS PER KDIGO STAZE, AKI HAS BEEN DEFINED. INCREMENT OF ONE OR MORE STAZE OR REQUIREMENT OF RRT IS CONSIDERED AS PROGRESSION. REMAINING SAME STAZE IS CONSIDERED AS PERSISTENT. DECREMENT OF ONE OR MORE STAZE IS CONSIDERED AS IMPROVEMENT. |
| Secondary | Impact on AKI (Progression, Resolution, requirement of renal replacement therapy, (RRT) | Day 7 | AS PER KDIGO STAZE, AKI HAS BEEN DEFINED. INCREMENT OF ONE OR MORE STAZE OR REQUIREMENT OF RRT IS CONSIDERED AS PROGRESSION. REMAINING SAME STAZE IS CONSIDERED AS PERSISTENT. DECREMENT OF ONE OR MORE STAZE IS CONSIDERED AS IMPROVEMENT. |
| Secondary | Mortality | 28 days | |
| Secondary | Improvement in SOFA score | 24 hours | IMPROVEMENT BY ATLEAST 2 POINTS |
| Secondary | Improvement in SOFA score | Day 3 | IMPROVEMENT BY ATLEAST 2 POINTS |
| Secondary | Lactate clearance | 6 hours | |
| Secondary | Lactate clearance | 12 hours | DECREMENT OF 25% LACATATE DELTA LACTATE = CURRENT LACTATE/BASELINE LACTATE \*100% |
| Secondary | Lactate clearance | 24 hous | DECREMENT OF 25% LACATATE DELTA LACTATE = CURRENT LACTATE/BASELINE LACTATE \*100% |
| Secondary | Lactate clearance | 72 hours | DECREMENT OF 25% LACATATE DELTA LACTATE = CURRENT LACTATE/BASELINE LACTATE \*100% |
| Secondary | Days of mechanical ventilation | 1 year | |
| Secondary | Days of Intensive Care Unit stay | 1 month |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04819568/registered